Clinical trials: Social Anxiety
Social Anxiety Disorder
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
This study evaluates the safety and tolerability of PH94B with repeated dosing over a period of up to 12 months. Participating subjects will use PH94B up to 4 times a day when they encounter anxiety-provoking situations in daily…
- Trial name
- NCT05030350
- Testing
- PH94B
- Where
- 3 sites in United States
- Volunteers
- 481 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of…
- Trial name
- AFFIRM-1 (NCT06510504)
- Testing
- 225 mg BNC210
- Where
- 21 sites in United States
- Volunteers
- 370 people
- Sponsor
- Bionomics Limited
Social Anxiety Disorder
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to…
- Trial name
- NCT06809179
- Testing
- Fasedienol Nasal Spray - Fasedienol Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder (SAD)
A Study of ONO-1110 in Patients With Social Anxiety Disorder
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Social Anxiety Disorder
- Trial name
- NCT06805565
- Testing
- ONO-1110
- Where
- 27 sites in Japan
- Volunteers
- 115 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Social Anxiety Disorder (SAD)
A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.
This study is to compare two Virtual Reality (VR)-based interventions, BVR-100 and BES-100, for the treatment of Social Anxiety Disorder (SAD).
- Trial name
- BVR-100-102 (NCT06037668)
- Testing
- BVR-100, BES-100
- Where
- 6 sites in United States
- Volunteers
- 56 people
- Sponsor
- Sumitomo Pharma America, Inc.
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Performance Anxiety
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.
- Trial name
- NCT04800237
- Testing
- VQW-765
- Where
- 15 sites in United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Social Anxiety Disorder
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in…
- Trial name
- PALISADE-3 (NCT06358651)
- Testing
- Fasedienol Nasal Spray
- Where
- 24 sites in United States
- Volunteers
- 238 people
- Sponsor
- VistaGen Therapeutics, Inc.
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mood, Depression Disorders
Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study
The goal of this study is to understand how children's mobile device usage (smartphones or tablets), including social media use and online games, are related to their mental wellness and mental health, as well as some aspects of…
- Conditions
- Mood, Depression Disorders, Anxiety Disorders, Sleep
- Trial name
- TECHWISE (NCT06664944)
- Where
- United States
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- Aura
Social Anxiety Disorder
Escitalopram in Patients With Social Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment…
- Trial name
- NCT00902226
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Social Anxiety Disorder
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with…
- Trial name
- NCT00302770
- Testing
- quetiapine
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Social Anxiety Disorder
Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
This is a Phase 1b/2a clinical trial to evaluate the safety, tolerability, and efficacy of RLS103 (cannabidiol [CBD] inhaled dry powder) to relieve the anxiety induced by a public speaking challenge in adults with social anxiety…
- Trial name
- NCT05429788
- Testing
- Low dose RLS103, High dose RLS103
- Where
- 3 sites in United States
- Sponsor
- Receptor Life Sciences
Depression in Adolescence, Anxiety
Application for Arts-Based Social Prescribing
The goal of this clinical trial is to learn if a personalized arts-based social prescribing program, Art Pharmacy, delivered through a mobile app (SocialRx App) can improve mental health and social connectedness in adolescents…
- Conditions
- Depression in Adolescence, Anxiety, Loneliness, Social Connectedness
- Trial name
- NCT07593443
- Testing
- Art Pharmacy, Stable treatment
- Volunteers
- 230 people
- Sponsor
- SocialRx Inc
Social Anxiety Disorder, Anxiety Disorders
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder
- Trial name
- NCT00273039
- Testing
- paroxetine
- Where
- 27 sites in United States, Argentina and 4 more
- Volunteers
- 242 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder
This Phase 2 study (protocol number EMP-01-201) will determine the safety and tolerability of a short-term treatment with an oral dosage form of EMP-01 in adult participants with social anxiety disorder (SAD) and will assess…
- Trial name
- NCT06693609
- Testing
- EMP-01
- Where
- 7 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- atai Therapeutics, Inc.
Emotional Dysregulation, Therapeutic Alliance
Effectiveness of the SoundHeal Multi-Sensory Integrative Therapy Among Justice-Involved Youth
Emotional dysregulation in justice-involved youth (JIY) is a condition that significantly impacts young people, their families, and juvenile justice and public health systems.
- Conditions
- Emotional Dysregulation, Therapeutic Alliance, Depression Disorder, Anxiety Disorders
- Trial name
- HEAL-SLOJSC (NCT07364799)
- Testing
- Multi-sensory emotional regulation intervention (Heal)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- SoundHeal
Social Phobia
Treatment Of Patients With Social Anxiety Disorder
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
- Trial name
- NCT00397722
- Testing
- GW876008, paroxetine
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 299 people
- Sponsor
- GlaxoSmithKline
Social Phobia
VR Mind and VR Mind+ Intervention
The aim of the study is to assess the safety and efficacy of VR Mind and VR Mind + interventions.
- Trial name
- NCT03895957
- Testing
- Virtual Reality Exposure Therapy VR Mind+, Virtual Reality Exposure Therapy VR Mind, Cognitive Behavioral Therapy
- Where
- 2 sites in Poland
- Volunteers
- 90 people
- Sponsor
- Tomorrow Sp. z o.o.